Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion

Bahareh Sayyar, Megan Dodd, Jianping Wen, Shirley Ma, Leah Marquez-Curtis, Anna Janowska-Wieczorek, Gonzalo Hortelano

    Research output: Contribution to journalArticle

    19 Citations (Scopus)

    Abstract

    Cell microencapsulation holds significant promise as a strategy for cellular therapies; however, inadequate survival and functionality of the enclosed cells limit its application in hemophilia treatment. Here, we evaluated the use of alginatebased microcapsules to enhance the viability and transgene secretion of human cord blood-derived mesenchymal stem cells in three-dimensional cultures. Given the positive effects of extracellular matrix molecules on mesenchymal stem cell growth, we tested whether fibrinogen-supplemented alginate microcapsules can improve the efficiency of encapsulated factor IX-engineered mesenchymal stem cells as a treatment of hemophilia B. We found that fibrinogen-supplemented alginate microcapsules (a) significantly enhanced the viability and proliferation of factor IX-engineered mesenchymal stem cells and (b) increased factor IX secretion by mesenchymal stem cells compared to mesenchymal stem cells in nonsupplemented microcapsules. Moreover, we observed the osteogenic, but not chondrogenic or adipogenic, differentiation capability of factor IX-engineered cord blood mesenchymal stem cells and their efficient factor IX secretion while encapsulated in fibrinogen-supplemented alginate microcapsules. Thus, the use of engineered mesenchymal stem cells encapsulated in fibrinogen-modified microcapsules may have potential application in the treatment of hemophilia or other protein deficiency diseases.

    Original languageEnglish
    Pages (from-to)1-12
    Number of pages12
    JournalJournal of Tissue Engineering
    Volume3
    Issue number1
    DOIs
    Publication statusPublished - 2012

    Fingerprint

    Factor IX
    Alginate
    Stem cells
    Mesenchymal Stromal Cells
    Transgenes
    Encapsulation
    Fibrinogen
    Capsules
    Hemophilia A
    Fetal Blood
    Blood
    Deficiency Diseases
    Hemophilia B
    Microencapsulation
    Protein Deficiency
    Drug Compounding
    alginic acid
    Cell growth
    Cell culture
    Extracellular Matrix

    Keywords

    • Alginate
    • Cell encapsulation
    • Fibrinogen
    • Hemophilia
    • Mesenchymal stem cells

    ASJC Scopus subject areas

    • Medicine (miscellaneous)
    • Biomaterials
    • Biomedical Engineering

    Cite this

    Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion. / Sayyar, Bahareh; Dodd, Megan; Wen, Jianping; Ma, Shirley; Marquez-Curtis, Leah; Janowska-Wieczorek, Anna; Hortelano, Gonzalo.

    In: Journal of Tissue Engineering, Vol. 3, No. 1, 2012, p. 1-12.

    Research output: Contribution to journalArticle

    Sayyar, Bahareh ; Dodd, Megan ; Wen, Jianping ; Ma, Shirley ; Marquez-Curtis, Leah ; Janowska-Wieczorek, Anna ; Hortelano, Gonzalo. / Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion. In: Journal of Tissue Engineering. 2012 ; Vol. 3, No. 1. pp. 1-12.
    @article{b0060d0a7d76475d97dbf3a0c87ca460,
    title = "Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion",
    abstract = "Cell microencapsulation holds significant promise as a strategy for cellular therapies; however, inadequate survival and functionality of the enclosed cells limit its application in hemophilia treatment. Here, we evaluated the use of alginatebased microcapsules to enhance the viability and transgene secretion of human cord blood-derived mesenchymal stem cells in three-dimensional cultures. Given the positive effects of extracellular matrix molecules on mesenchymal stem cell growth, we tested whether fibrinogen-supplemented alginate microcapsules can improve the efficiency of encapsulated factor IX-engineered mesenchymal stem cells as a treatment of hemophilia B. We found that fibrinogen-supplemented alginate microcapsules (a) significantly enhanced the viability and proliferation of factor IX-engineered mesenchymal stem cells and (b) increased factor IX secretion by mesenchymal stem cells compared to mesenchymal stem cells in nonsupplemented microcapsules. Moreover, we observed the osteogenic, but not chondrogenic or adipogenic, differentiation capability of factor IX-engineered cord blood mesenchymal stem cells and their efficient factor IX secretion while encapsulated in fibrinogen-supplemented alginate microcapsules. Thus, the use of engineered mesenchymal stem cells encapsulated in fibrinogen-modified microcapsules may have potential application in the treatment of hemophilia or other protein deficiency diseases.",
    keywords = "Alginate, Cell encapsulation, Fibrinogen, Hemophilia, Mesenchymal stem cells",
    author = "Bahareh Sayyar and Megan Dodd and Jianping Wen and Shirley Ma and Leah Marquez-Curtis and Anna Janowska-Wieczorek and Gonzalo Hortelano",
    year = "2012",
    doi = "10.1177/2041731412462018",
    language = "English",
    volume = "3",
    pages = "1--12",
    journal = "Journal of Tissue Engineering",
    issn = "2041-7314",
    publisher = "SAGE-Hindawi Access to Research",
    number = "1",

    }

    TY - JOUR

    T1 - Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion

    AU - Sayyar, Bahareh

    AU - Dodd, Megan

    AU - Wen, Jianping

    AU - Ma, Shirley

    AU - Marquez-Curtis, Leah

    AU - Janowska-Wieczorek, Anna

    AU - Hortelano, Gonzalo

    PY - 2012

    Y1 - 2012

    N2 - Cell microencapsulation holds significant promise as a strategy for cellular therapies; however, inadequate survival and functionality of the enclosed cells limit its application in hemophilia treatment. Here, we evaluated the use of alginatebased microcapsules to enhance the viability and transgene secretion of human cord blood-derived mesenchymal stem cells in three-dimensional cultures. Given the positive effects of extracellular matrix molecules on mesenchymal stem cell growth, we tested whether fibrinogen-supplemented alginate microcapsules can improve the efficiency of encapsulated factor IX-engineered mesenchymal stem cells as a treatment of hemophilia B. We found that fibrinogen-supplemented alginate microcapsules (a) significantly enhanced the viability and proliferation of factor IX-engineered mesenchymal stem cells and (b) increased factor IX secretion by mesenchymal stem cells compared to mesenchymal stem cells in nonsupplemented microcapsules. Moreover, we observed the osteogenic, but not chondrogenic or adipogenic, differentiation capability of factor IX-engineered cord blood mesenchymal stem cells and their efficient factor IX secretion while encapsulated in fibrinogen-supplemented alginate microcapsules. Thus, the use of engineered mesenchymal stem cells encapsulated in fibrinogen-modified microcapsules may have potential application in the treatment of hemophilia or other protein deficiency diseases.

    AB - Cell microencapsulation holds significant promise as a strategy for cellular therapies; however, inadequate survival and functionality of the enclosed cells limit its application in hemophilia treatment. Here, we evaluated the use of alginatebased microcapsules to enhance the viability and transgene secretion of human cord blood-derived mesenchymal stem cells in three-dimensional cultures. Given the positive effects of extracellular matrix molecules on mesenchymal stem cell growth, we tested whether fibrinogen-supplemented alginate microcapsules can improve the efficiency of encapsulated factor IX-engineered mesenchymal stem cells as a treatment of hemophilia B. We found that fibrinogen-supplemented alginate microcapsules (a) significantly enhanced the viability and proliferation of factor IX-engineered mesenchymal stem cells and (b) increased factor IX secretion by mesenchymal stem cells compared to mesenchymal stem cells in nonsupplemented microcapsules. Moreover, we observed the osteogenic, but not chondrogenic or adipogenic, differentiation capability of factor IX-engineered cord blood mesenchymal stem cells and their efficient factor IX secretion while encapsulated in fibrinogen-supplemented alginate microcapsules. Thus, the use of engineered mesenchymal stem cells encapsulated in fibrinogen-modified microcapsules may have potential application in the treatment of hemophilia or other protein deficiency diseases.

    KW - Alginate

    KW - Cell encapsulation

    KW - Fibrinogen

    KW - Hemophilia

    KW - Mesenchymal stem cells

    UR - http://www.scopus.com/inward/record.url?scp=84889012204&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84889012204&partnerID=8YFLogxK

    U2 - 10.1177/2041731412462018

    DO - 10.1177/2041731412462018

    M3 - Article

    VL - 3

    SP - 1

    EP - 12

    JO - Journal of Tissue Engineering

    JF - Journal of Tissue Engineering

    SN - 2041-7314

    IS - 1

    ER -